Abbott Labs Reports Officer and Director Changes

Ticker: ABT · Form: 8-K · Filed: 2024-05-01T00:00:00.000Z

Sentiment: neutral

Topics: corporate-governance, officer-changes, director-changes

Related Tickers: ABT

TL;DR

ABT filed an 8-K for officer/director changes effective 4/26.

AI Summary

Abbott Laboratories filed an 8-K on May 1, 2024, reporting changes effective April 26, 2024. The filing pertains to the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements for certain officers. Specific details regarding the individuals involved, their roles, and the nature of the compensatory arrangements are not provided in this excerpt.

Why It Matters

Changes in a company's board of directors and executive officers can signal shifts in strategy, governance, or operational focus.

Risk Assessment

Risk Level: low — This filing reports routine corporate governance changes and does not indicate any immediate financial distress or significant operational disruption.

Key Players & Entities

FAQ

What specific officer or director positions were affected by the changes reported on April 26, 2024?

The filing indicates changes related to 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers,' but the specific names and positions are not detailed in this excerpt.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this filing was on April 26, 2024.

What is the primary business of Abbott Laboratories according to the filing?

Abbott Laboratories is classified under the Standard Industrial Classification code 2834, which is 'PHARMACEUTICAL PREPARATIONS'.

What is the fiscal year end for Abbott Laboratories?

The fiscal year end for Abbott Laboratories is December 31.

What is the SEC file number for Abbott Laboratories?

The SEC file number for Abbott Laboratories is 001-02189.

From the Filing

0001104659-24-055724.txt : 20240501 0001104659-24-055724.hdr.sgml : 20240501 20240501160209 ACCESSION NUMBER: 0001104659-24-055724 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240426 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20240501 DATE AS OF CHANGE: 20240501 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ABBOTT LABORATORIES CENTRAL INDEX KEY: 0000001800 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 360698440 STATE OF INCORPORATION: IL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-02189 FILM NUMBER: 24902851 BUSINESS ADDRESS: STREET 1: 100 ABBOTT PARK ROAD CITY: ABBOTT PARK STATE: IL ZIP: 60064-3500 BUSINESS PHONE: 2246676100 MAIL ADDRESS: STREET 1: 100 ABBOTT PARK ROAD CITY: ABBOTT PARK STATE: IL ZIP: 60064-3500 8-K 1 tm2413230d1_8k.htm FORM 8-K false 0000001800 Common Shares, Without Par Value ABT 0000001800 2024-04-26 2024-04-26 0000001800 us-gaap:CommonStockMember exch:XCHI 2024-04-26 2024-04-26 0000001800 us-gaap:CommonStockMember exch:XNYS 2024-04-26 2024-04-26 iso4217:USD xbrli:shares iso4217:USD xbrli:shares Common Shares, Without Par Value   ABT       UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549       FORM  8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   April 26, 2024 Date of Report (Date of earliest event reported)     ABBOTT LABORATORIES (Exact name of registrant as specified in charter)       Illinois   1-2189   36-0698440 (State or other Jurisdiction   (Commission File Number)   (IRS Employer of Incorporation)       Identification No.)       100 Abbott Park Road Abbott Park , Illinois 60064-6400 (Address of principal executive offices)(Zip Code)   Registrant’s telephone number, including area code:  ( 224 ) 667-6100   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ¨         Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ¨         Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ¨         Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ¨         Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities Registered Pursuant to Section 12(b) of the Act:   Title of Each Class Trading Symbol(s) Name of Each Exchange  on Which Registered Common Shares, Without Par Value ABT New York Stock Exchange Chicago Stock Exchange, Inc.   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company   ¨   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ¨             Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appo

View on Read The Filing